Type 2 diabete mellitus
Conditions
Interventions
To compare the DPP-4 inhibitor monotherapy group with the imeglimin addition group
Sponsors
Shimoda Masashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Outpatients diagnosed with type 2 diabetes mellitus who are 20 years of age or older at the time of consent 2) Patients who have been taking DPP-4 inhibitors for at least 12 weeks at the start of study treatment 3) Patients who have been on a diet and exercise regimen for at least 12 weeks at the start of study treatment 4)Patients with an HbA1c level between 7.0% and 9.0% on the test measured at the eligibility test 5) Patients with an HbA1c level within 10% of the variability between the HbA1c level measured most recently at the eligibility test and the HbA1c level measured at the time of the eligibility test between 10 weeks and 4 weeks prior to the eligibility test 6) Patients who have given written consent to participate in this study.
Exclusion criteria
Exclusion criteria: 1) Patients with type 1 diabetes mellitus 2) Patients taking two or more oral hypoglycemic agents other than DPP-4 inhibitors at the time of consent 3) Patients who have been taking an oral hypoglycaemic drug other than a DPP-4 inhibitor within 12 weeks prior to the start of study treatment 4) Patients who have received a glucagon-like peptide receptor agonist or insulin within the last 6 months 5) Patients with proliferative retinopathy 6) Patients with severe diabetic neuropathy 7) Patients with contraindications to Imeglimin 8) Patients with impaired renal function, including patients on dialysis at the time of eligibility testing 9) Patients with severe hepatic impairment 10) Patients with New York Heart Association (NYHA) grade III or IV cardiac function at last evaluation within the last year 11) Excessive and regular drinkers 12) Pregnant women and patients who may be pregnant or lactating. 13) Patients with malignant tumours undergoing or within 5 years of completion of treatment. 14) Patients who are participating in a clinical study involving other interventions. 15) Any other patients who are deemed unsuitable for this study by the principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured from baseline in HbA1c level at 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Measured in HbA1c level from baseline (at regular visit) 2) Measured value of HbA1c level (at regular visit) 3) Percentage of patients achieving HbA1c target (<7.0% / <6.0%) (at 0, 24, 52 and 104 weeks) 4) Measured fasting blood glucose and change from baseline (at regular visits) 5) Measured change from baseline in glycoalbumin levels (at regular visits) 6) Measured value and change from baseline in area under the curve (AUC0-3h) from 0 to 3 hours postprandial blood glucose during the meal load test and change from baseline (at 24, 52 and 104 weeks) 7) Measured value and change from baseline of postprandial serum insulin level AUC0-3h during the meal load test (24, 52, 104 weeks) AUC0-3h and change from baseline (at 24, 52 and 104 weeks) 8) Measured postprandial serum Insulinogenic index and change from baseline at 24, 52 and 104 weeks at 24, 52 and 104 weeks) 9) Measured value and change from baseline in Matsuda index at 24, 52 and 104 weeks during a food challenge test 10) Measured value and change from baseline in HOMA-IR at 24, 52 and 104 weeks 11) Measured value and change from baseline of HOMA-beta at 24, 52 and 104 weeks | — |
Contacts
Public ContactMasashi Shimoda
Kawasaki Medical School Hospital
Outcome results
None listed